Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting

by | Apr 17, 2018 | Globe Newswire

Cancer cells deficient in BRCA1 or BRCA2 function hyper-sensitive to APTO-253 

Cancer cells deficient in BRCA1 or BRCA2 function hyper-sensitive to APTO-253